Date:			2/17/2022			
Your Name:			Feng Lu			
Manuscript Title:			Hypomethylation-induced prognostic mark contributes to glioblastoma progression	er zinc finger DHHC-type palmitoyltransferase 12		
Maı	nuscript Number (if I	known):				
content of your manuscript. "Re affected by the content of the m indicate a bias. If you are in dou The author's relationships/activi epidemiology of hypertension, you that medication is not mentioned."		ript. "Rela of the mar e in doubt os/activitie ension, you entioned	ted" means any relation with for-profit or no nuscript. Disclosure represents a commitme about whether to list a relationship/activity es/interests should be defined broadly. For each should declare all relationships with manufain the manuscript.	/interest, it is preferable that you do so.		
			entities with whom you have this thip or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)		
			Time frame: Since the initial planning	of the work		
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	⊠ No	one			
			Time frame: past 36 month	ns		
2	Grants or contracts from any entity (if not indicated in item #1 above).	× No	one			
3	Royalties or licenses	⊠ No	one			

		Name all entities with whom you have this relationship or indicate none (add rows as needed) Specifications/Comments (e.g., if payments we made to you or to your institution)	ere
4	Consulting fees	None None	
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	None None	
6	Payment for expert testimony	None None	
7	Support for attending meetings and/or travel	None None	
8	Patents planned, issued or pending	None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	None None	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	None None	

			e all entities with whom you have this onship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)		
11	Stock or stock options		None			
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services		None			
13	Other financial or non-financial interests		None			
Plea	Please place an "X" next to the following statement to indicate your agreement:					

I certify that I have answered every question and have not altered the wording of any of the questions on this form.

Feng Lu

Date:		2/17/2022			
Your Name: Manuscript Title:		Shang-Hang Shen			
		Hypomethylation-induced prognostic marker zinc finger DHHC-type palmitoyltransferase 12 contributes to glioblastoma progression			
Mai	nuscript Number (if l	nown):			
content of your manuscript. "Re affected by the content of the maindicate a bias. If you are in double the author's relationships/activit epidemiology of hypertension, you that medication is not mentioned."		all support for the work reported in this manuscript without time limit. For all other items, the time			
		Name all entities with whom you have this relationship or indicate none (add rows as needed) Specifications/Comments (e.g., if payments were made to you or to your institution)			
		Time frame: Since the initial planning of the work			
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	None None			
		Time frame: past 36 months			
2	Grants or contracts from any entity (if not indicated in item #1 above).	None None			
3	Royalties or licenses	None None			

		Name all entities with whom you have this relationship or indicate none (add rows as needed) Specifications/Comments (e.g., if payments we made to you or to your institution)	ere
4	Consulting fees	None None	
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	None None	
6	Payment for expert testimony	None None	
7	Support for attending meetings and/or travel	None None	
8	Patents planned, issued or pending	None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	None None	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	None None	

			e all entities with whom you have this onship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
11	Stock or stock options		None	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services		None	
13	Other financial or non-financial interests		None	
Plea ⊠	Please place an "X" next to the following statement to indicate your agreement: I certify that I have answered every question and have not altered the wording of any of the questions on this form.			

Theng Hong Shen

Pate: Your Name: Manuscript Title:		2/17/2022				
		Shizhong Wu	Shizhong Wu			
		Hypomethylation-induced prognostic marker zinc finger DHHC-type palmitoyltransf contributes to glioblastoma progression	erase 12			
Mai	nuscript Number (if l	nown):				
content of your manuscript. "R affected by the content of the r indicate a bias. If you are in dor The author's relationships/active epidemiology of hypertension, that medication is not mentioned.		all support for the work reported in this manuscript without time limit. For all other items, th	s may be urily he , even if			
		Name all entities with whom you have this relationship or indicate none (add rows as needed) Specifications/Comments (e.g., if pay made to you or to your institution)	ments were			
		Time frame: Since the initial planning of the work				
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	None				
		Time frame: past 36 months				
2	Grants or contracts from any entity (if not indicated in item #1 above).	None None				
3	Royalties or licenses	None None				

		Name all entities with whom you have this relationship or indicate none (add rows as needed) Specifications/Comments (e.g., if payments we made to you or to your institution)	ere
4	Consulting fees	None None	
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	None None	
6	Payment for expert testimony	None None	
7	Support for attending meetings and/or travel	None None	
8	Patents planned, issued or pending	None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	None None	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	None None	

			e all entities with whom you have this ionship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)	
11	Stock or stock options		None		
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services		None		
13	Other financial or non-financial interests		None		
Plea 🖂	Please place an "X" next to the following statement to indicate your agreement: I certify that I have answered every question and have not altered the wording of any of the questions on this form.				

Jackong Un

Date:		2/17/2022				
Your Name: Manuscript Title:		Pengfeng Zheng	Pengfeng Zheng Hypomethylation-induced prognostic marker zinc finger DHHC-type palmitoyltransferase 12 contributes to glioblastoma progression			
Mai	nuscript Number (if l	nown):				
content of your manuscript. "Reaffected by the content of the mindicate a bias. If you are in dou The author's relationships/activepidemiology of hypertension, you that medication is not mentioned."		all support for the work reported in this manuscript without time limit. For all other items, the time	oe			
		Name all entities with whom you have this relationship or indicate none (add rows as needed) Specifications/Comments (e.g., if payments made to you or to your institution)	were			
		Time frame: Since the initial planning of the work				
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	None None				
		Time frame: past 36 months				
2	Grants or contracts from any entity (if not indicated in item #1 above).	None None				
3	Royalties or licenses	None None				

		Name all entities with whom you have this relationship or indicate none (add rows as needed) Specifications/Comments (e.g., if payments we made to you or to your institution)	ere
4	Consulting fees	None None	
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	None None	
6	Payment for expert testimony	None None	
7	Support for attending meetings and/or travel	None None	
8	Patents planned, issued or pending	None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	None None	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	None None	

			e all entities with whom you have this onship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
11	Stock or stock options		None	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services		None	
13	Other financial or non-financial interests		None	
Plea ⊠	Please place an "X" next to the following statement to indicate your agreement: I certify that I have answered every question and have not altered the wording of any of the questions on this form.			

Pengteng Ebey

Date:			2/17/2022			
Your Name:			Kun Lin			
Manuscript Title:			Hypomethylation-induced prognostic mark contributes to glioblastoma progression	Hypomethylation-induced prognostic marker zinc finger DHHC-type palmitoyltransferase 12 contributes to glioblastoma progression		
Mai	nuscript Number (if	known):			
con affe indi The epic that	In the interest of transparency, we content of your manuscript. "Relaffected by the content of the maindicate a bias. If you are in doub." The author's relationships/activit epidemiology of hypertension, you that medication is not mentioned.		manuscript. Disclosure represents a commitme ubt about whether to list a relationship/activity vities/interests should be defined broadly. For eyou should declare all relationships with manufed in the manuscript.	ot-for-profit third parties whose interests may be nt to transparency and does not necessarily /interest, it is preferable that you do so. example, if your manuscript pertains to the facturers of antihypertensive medication, even if		
			e all entities with whom you have this onship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)		
			Time frame: Since the initial planning	of the work		
1	All support for the present manuscript (e.g.,		None			
	funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.					
	of study materials, medical writing, article processing charges, etc.) No time limit for		Time frame: past 36 month			
2	of study materials, medical writing, article processing charges, etc.) No time limit for		Time frame: past 36 month None			

		Name all entities with whom you have this relationship or indicate none (add rows as needed) Specifications/Comments (e.g., if payments we made to you or to your institution)	ere
4	Consulting fees	None None	
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	None None	
6	Payment for expert testimony	None None	
7	Support for attending meetings and/or travel	None None	
8	Patents planned, issued or pending	None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	None None	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	None None	

			e all entities with whom you have this ionship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)	
11	Stock or stock options		None		
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services		None		
13	Other financial or non-financial interests		None		
Plea 🖂	Please place an "X" next to the following statement to indicate your agreement: \[\sum \] I certify that I have answered every question and have not altered the wording of any of the questions on this form.				

Kun Lin

Date:		2/17/2022			
Your Name:		Jingwei Liao			
Manuscript Title:		Hypomethylation-induced prognostic marker zinc finger DHHC-type palmitoyltransferase 12 contributes to glioblastoma progression			
Maı	nuscript Number (if I	nown):			
content of your manuscript. "Rel affected by the content of the maindicate a bias. If you are in doub." The author's relationships/activit epidemiology of hypertension, you that medication is not mentioned.		all support for the work reported in this manuscript without time limit. For all other items, the time			
		Name all entities with whom you have this relationship or indicate none (add rows as needed) Specifications/Comments (e.g., if payments were made to you or to your institution)			
		Time frame: Since the initial planning of the work			
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	None None			
		Time frame: past 36 months			
2	Grants or contracts from any entity (if not indicated in item #1 above).	None			
3	Royalties or licenses	None None			

			ifications/Comments (e.g., if payments were e to you or to your institution)
4	Consulting fees	None	
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	None	
6	Payment for expert testimony	None None	
7	Support for attending meetings and/or travel	None ■	
8	Patents planned, issued or pending	None ■	
9	Participation on a Data Safety Monitoring Board or Advisory Board	None	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	None ■	

		same all entities with whom you have this lationship or indicate none (add rows as needed) Specifications/Comments (e.g., if payments we made to you or to your institution)	ere			
11	Stock or stock options	None				
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	None ————————————————————————————————————				
13	Other financial or non-financial interests	None				
Plea	Please place an "X" next to the following statement to indicate your agreement:					

I certify that I have answered every question and have not altered the wording of any of the questions on this form.

Digne Lian

Date:		2/17/2022				
Your Name:		Xiaohang Jiang	Xiaohang Jiang			
Manuscript Title:		Hypomethylation-induced prognostic marker zinc finger DHHC-type palmitoyltransferase contributes to glioblastoma progression	Hypomethylation-induced prognostic marker zinc finger DHHC-type palmitoyltransferase 12 contributes to glioblastoma progression			
Mai	nuscript Number (if l	nown):				
In the interest of transparency, we content of your manuscript. "Reaffected by the content of the maindicate a bias. If you are in double the author's relationships/activitiepidemiology of hypertension, you that medication is not mentioned."		all support for the work reported in this manuscript without time limit. For all other items, the time	ated" means any relation with for-profit or not-for-profit third parties whose interests may be inuscript. Disclosure represents a commitment to transparency and does not necessarily about whether to list a relationship/activity/interest, it is preferable that you do so. dies/interests should be defined broadly. For example, if your manuscript pertains to the bushould declare all relationships with manufacturers of antihypertensive medication, even if a in the manuscript. Out for the work reported in this manuscript without time limit. For all other items, the time			
		Name all entities with whom you have this relationship or indicate none (add rows as needed) Specifications/Comments (e.g., if payments made to you or to your institution)	were			
		Time frame: Since the initial planning of the work				
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	None None				
		Time frame: past 36 months				
2	Grants or contracts from any entity (if not indicated in item #1 above).	None None				
3	Royalties or licenses	None None				

		Name all entities with whom you have this relationship or indicate none (add rows as needed) Specifications/Comments (e.g., if payments we made to you or to your institution)	ere
4	Consulting fees	None None	
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	None None	
6	Payment for expert testimony	None None	
7	Support for attending meetings and/or travel	None None	
8	Patents planned, issued or pending	None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	None None	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	None None	

		Name all entities with whom you have this relationship or indicate none (add rows as needed) Specifications/Comments (e.g., if payments were made to you or to your institution)			
11	Stock or stock options	None None			
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	None			
13	Other financial or non-financial interests	None			
Please place an "X" next to the following statement to indicate your agreement:					

I certify that I have answered every question and have not altered the wording of any of the questions on this form.

Xiaohang Jong

Date:		2/17/2022				
Your Name:		Guangming Zeng	Guangming Zeng			
Manuscript Title:		Hypomethylation-induced prognostic marker zinc finger DHHC-type palmitoylt contributes to glioblastoma progression	Hypomethylation-induced prognostic marker zinc finger DHHC-type palmitoyltransferase 12 contributes to glioblastoma progression			
Mai	nuscript Number (if l	known):				
In the interest of transparency, we content of your manuscript. "Reaffected by the content of the mindicate a bias. If you are in double the author's relationships/activitiepidemiology of hypertension, you that medication is not mentioned."		ipt. "Related" means any relation with for-profit or not-for-profit third parties whose int of the manuscript. Disclosure represents a commitment to transparency and does not nee in doubt about whether to list a relationship/activity/interest, it is preferable that you dos/activities/interests should be defined broadly. For example, if your manuscript pertain nsion, you should declare all relationships with manufacturers of antihypertensive medic entioned in the manuscript. all support for the work reported in this manuscript without time limit. For all other item	ies/interests should be defined broadly. For example, if your manuscript pertains to the bu should declare all relationships with manufacturers of antihypertensive medication, even if in the manuscript. Out for the work reported in this manuscript without time limit. For all other items, the time			
		Name all entities with whom you have this relationship or indicate none (add rows as needed) Specifications/Comments (e.g., i made to you or to your institution)				
		Time frame: Since the initial planning of the work				
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	None None				
		Time frame: past 36 months				
2	Grants or contracts from any entity (if not indicated in item #1 above).	None				
3	Royalties or licenses	None				

		Name all entities with whom you have this relationship or indicate none (add rows as needed) Specifications/Comments (e.g., if payments we made to you or to your institution)	ere
4	Consulting fees	None None	
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	None None	
6	Payment for expert testimony	None None	
7	Support for attending meetings and/or travel	None None	
8	Patents planned, issued or pending	None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	None None	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	None None	

			e all entities with whom you have this ionship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)	
11	Stock or stock options		None		
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services		None		
13	Other financial or non-financial interests		None		
Plea 🖂	Please place an "X" next to the following statement to indicate your agreement: \[\sum I certify that I have answered every question and have not altered the wording of any of the questions on this form.				

Coloned Son

Date:			2/17/2022			
Your Name:			De Wei			
Manuscript Title:			Hypomethylation-induced prognostic marker zinc finger DHHC-type palmitoyltransferase 12 contributes to glioblastoma progression			
Ma	nuscript Number (if I	known)				
con affe indi	tent of your manuscrected by the content of cate a bias. If you are	ript. "Ro of the m e in dou		/interest, it is preferable that you do so.		
-	demiology of hyperte t medication is not m	-		acturers of antihypertensive medication, even if		
In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.						
			all entities with whom you have this nship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)		
			Time frame: Since the initial planning	of the work		
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)		None			
	No time limit for this item.					
			Time frame: past 36 month	ns		
2			Time frame: past 36 month	ns		

			Comments (e.g., if payments were to your institution)
4	Consulting fees	None None	
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	None None	
6	Payment for expert testimony	None None	
7	Support for attending meetings and/or travel	None None	
8	Patents planned, issued or pending	None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	None None	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	None None	

			e all entities with whom you have this onship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)	
11	Stock or stock options		None		
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services		None		
13	Other financial or non-financial interests		None		
Please place an "X" next to the following statement to indicate your agreement: \[\text{\tint{\text{					

De Wed